Un ensayo clínico podría validar el uso del calcitriol, la forma activa de la vitamina D, para tratar la Ataxia de Friedreich, tal como propone el grupo de investigación Bioquímica del Estrés Oxidativo del Instituto de Investigación Biomédica de Lleida (IRBLleida) y la Universidad de Lleida (UdL). Su investigación es la base de este ensayo que realizarán la Unidad de Ataxias del Hospital Josep Trueta de Girona y del Hospital Santa Caterina del Parc Hospitalari Martí i Julià de Salt conjuntamente con el Instituto de Investigación Biomédica de Girona (IDIBGI).
Tuesday, June 8, 2021
Luz verde a un ensayo clínico con calcitriol para validar su potencial terapéutico para tratar la Ataxia de Friedreich
Comunicación y Prensa IRBLleida; Lunes, 7 de junio de 2021
A clinical trial with calcitriol has begun to validate its therapeutic potential for treating Friedreich's Ataxia
Biotech-spain.com; 07/06/2021
A clinical trial could validate the use of calcitriol, the active form of vitamin D, to treat Friedreich's Ataxia, as proposed by the Biochemistry of Oxidative Stress Group at the Biomedical Research Institute of Lleida (IRBLleida) and the University of Lleida (UdL). Their research is the basis of this trial to be carried out by the Ataxia Unit of the Josep Trueta Hospital in Girona and the Santa Caterina Hospital of the Parc Hospitalari Martí i Julià de Salt in conjunction with the Institute for Research in Biomedicine of Girona (IDIBGI).
6 Clinical presentation and outcomes of childhood hypertrophic cardiomyopathy associated with friedreich’s ataxia: a national cohort study
Rance T, Norrish G; Heart 2021;107:A5. doi:10.1136/heartjnl-2021-BCS.
This national study of childhood FA-HCM is the largest cohort reported to date and describes a high prevalence of atrial arrhythmias and early progression to end-stage disease. Overall mortality is similar to that reported in non-syndromic childhood HCM but no patients died suddenly.
Subscribe to:
Posts (Atom)
